N0 | 18 | 36% | 18 | (82.6%) | 0 | (0%) | 0.002§ |
N1 | 6 | 12% | 2 | (8.7%) | 4 | (13.5%) | |
N2 | 16 | 32% | 1 | (4.3%) | 15 | (54.1%) | |
N3 | 10 | 20% | 0 | (4.3%) | 10 | (32.4%) | |
Lymph node |
|
|
|
|
|
|
|
Negative | 18 | 36% | 18 | (82.6%) | 0 | (0%) | <0.001‡ |
Positive | 32 | 64% | 2 | (17.4%) | 30 | (83%) | |
M |
|
|
|
|
|
|
|
M0 | 40 | 80% | 26 | (55.3%) | 21 | (44.7%) | 0.04‡ |
M1 | 10 | 20% | 2 | (15.4%) | 11 | (48.6%) | |
AJCC Stage group |
|
|
|
|
|
|
|
Stage I | 8 | 16% | 9 | (39.1%) | 0 | (0%) | <0.001§ |
Stage II | 10 | 20% | 10 | (43.5%) | 4 | (10.8%) | |
Stage III | 22% | 44% | 4 | (17.4%) | 17 | (45.6%) | |
Stage IV | 10% | 20% | 0 | (0%) | 16 | (43.2%) | |
YKL-40 |
|
| 18 | (100%) | 5 | (27%) |
|
Low | 23 | 46% | 2 | (0%) | 25 | (73%) | <0.001‡ |
High | 27 | 54% | 9 | (39.1%) | 0 | (0%) |